InvestorsHub Logo
Followers 0
Posts 3
Boards Moderated 0
Alias Born 01/23/2019

Re: None

Wednesday, 01/23/2019 3:35:13 PM

Wednesday, January 23, 2019 3:35:13 PM

Post# of 2435
https://linc2019.cncptdlx.com/media/1515_Pavel_Ignatenko_22_01_2019_Room_6_-_Speakers_corner_v1.pdf

Intermediate results in the NSPR cguard v ABT acculink stent russian trial

NSPR is superior, lower lesions, no device related complications compared to Acculink.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NSPR News